Schistosomiasis
56
4
5
37
Key Insights
Highlights
Success Rate
97% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
1.8%
1 terminated out of 56 trials
97.4%
+10.8% vs benchmark
9%
5 trials in Phase 3/4
22%
8 of 37 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 37 completed trials
Clinical Trials (56)
Assessment of Right Ventricular-Pulmonary Arterial Coupling in Schistosomiasis-Associated Pulmonary Arterial Hypertension
Expanding Access to Preventive Chemotherapy Among Mobile and Migrant Populations
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of the rSm-p80 + GLA-SE (SchistoShield®) Candidate Vaccine in Healthy Adults in Burkina Faso and Madagascar
Praziquantel in Children Under Age 4
Prevalence and Molecular Identification of Human Schistosomiasis
Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective
Sm-TSP-2 Schistosomiasis Vaccine in Healthy Ugandan Adults
Health Education Model Led by Community Health Volunteers.
Introduction of Arpraziquantel Treatment for Schistosomiasis Control in Preschool-aged Children in Endemic Areas: A Small-scale Public Health Intervention Study
Safety, Tolerability, and Immunogenicity Study of Sm-p80 + GLA-SE (SchistoShield(R)) Vaccine in Healthy Adults
Delivering a Multi-disease Screening Tool to Migrant Populations
Assessment of Infection Activity in Travelers and Migrants Diagnosed With Chronic Schistosomiasis
Female Genital Schistosomiasis in Migrant Women: A Pilot Study
Evaluation of a Comprehensive School Health Programme in Zambia
Single-sex Female Controlled Human Schistosomiasis Mansoni Infection
L-PZQ ODT in Schistosoma Infected Children
Effectiveness and Cost-effectiveness of Integrated Model for Malaria and Helminth Control
Sm-p80 Schistosomiasis Challenge Study
Schistosomiasis in Senegal
Repeated Controlled Human Schistosoma Mansoni Infection